60
Participants
Start Date
December 14, 2023
Primary Completion Date
March 20, 2025
Study Completion Date
August 28, 2025
Samuraciclib
Samuraciclib tablet by mouth once a day
Fulvestrant
Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
Semmelweis Egyetem, Budapest
Szent Borbala Korhaz, Tatabánya
Nograd Varmegyei Szent Lazar Korhaz, Salgótarján
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
Mfsmc-Hjwci, Baltimore
Trakya University, Edirne
MD Anderson Cancer Center, Madrid
Hospital Clinico San Carlos, Madrid
Hospital Vithas Málaga, Málaga
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi, Istanbul
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul
I.E.U. Medical Point Hastanesi, Izmir
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca
Hospital Universitario Marqués de Valdecilla, Santander
Actualidad Basada en la Investigación del Cáncer, Guadalajara
Renati Innovation S.A.P.I de C.V, Guadalajara
Hospital Clinico de Valencia, Valencia
Saint Luke's Cancer Institute, Kansas City
Oaxaca Site Management Organization S.C., Oaxaca City
Centro de Investigacion Clinica de Oaxaca, Oaxaca City
The Center for Cancer and Blood Disorders, Fort Worth
Soltmed SMO, Mexico City
Cryptex Investigación Clínica S.A. de C.V., Cuauhtémoc
Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat
Hospital Infanta Cristina, Badajoz
Parc de Salut Mar - Hospital del Mar, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Gulhane Egitim ve Arastirma Hastanesi, Ankara
Gazi University, Ankara
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi, Ankara
Hacettepe Universite Hastaneleri, Ankara
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
Carrick Therapeutics Limited
INDUSTRY